Across TCGA pan-cancer cohorts, PRR36 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRR36 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher PRR36 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRR36 expression acts as an unfavorable survival marker.

MESO and UCEC are the cancer types where PRR36 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	III,IV	0.082	0.414	.007	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: PRR36 tumor-vs-normal RNA expression · all PRR36 data types